How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses?

Immunology Letters

Volumn 163, Issue 1, 2015, Pages 69-75

  Makvandi Nejad, Shokouh ^a   Rowland Jones, Sarah ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HIV 1; HIV 2; Immune escape; Neutralising antibody; Viral diversity

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 125; GLYCOPROTEIN GP 36; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS ENVELOPE PROTEIN;

ANTIBODY DEPENDENT COMPLEMENT MEDIATED INACTIVATION; ANTIBODY RESPONSE; ARTICLE; COMPARATIVE STUDY; EPITOPE MAPPING; EVOLUTIONARY RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION CONTROL; NONHUMAN; OUTCOME ASSESSMENT; PHYLOGENY; STRUCTURE ACTIVITY RELATION; VIRUS ENVELOPE; VIRUS LOAD; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS VIRULENCE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; GENETICS; IMMUNOLOGY; MOLECULAR EVOLUTION; SPECIES DIFFERENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EVOLUTION, MOLECULAR; HIV-1; HIV-2; HUMANS; SPECIES SPECIFICITY;

EID: 84913557978     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.10.028     Document Type: Review

References (89)

1. Gao F., Yue L., Robertson D.L., Hill S.C., Hui H., Biggar R.J., et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994, 68:7433-7447.
2. Poulsen A.G., Aaby P., Gottschau A., Kvinesdal B.B., Dias F., Molbak K., et al. HIV-2 infection in Bissau, West Africa, 1987-1989: incidence, prevalences, and routes of transmission. J Acquir Immune Defic Syndr 1993, 6:941-948.
3. Pfutzner A., Dietrich U., von E.U., von B.H., Brede H.D., Maniar J.K., et al. HIV-1 and HIV-2 infections in a high-risk population in Bombay, India: evidence for the spread of HIV-2 and presence of a divergent HIV-1 subtype. J Acquir Immune Defic Syndr 1992, 5:972-977.
4. de Silva T., Weiss R.A. HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes. Indian J Med Res 2010, 132:660-662.
5. Valadas E., Franca L., Sousa S., Antunes F. 20 years of HIV-2 infection in Portugal: trends and changes in epidemiology. Clin Infect Dis 2009, 48:1166-1167.
6. Matheron S., Pueyo S., Damond F., Simon F., Lepretre A., Campa P., et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 2003, 17:2593-2601.
7. O'Brien T.R., George J.R., Holmberg S.D. Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications. JAMA 1992, 267:2775-2779.
8. Barin F., M'Boup S., Denis F., Kanki P., Allan J.S., Lee T.H., et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa. Lancet 1985, 2:1387-1389.
9. Kanki P.J., Barin F., M'Boup S., Allan J.S., Romet-Lemonne J.L., Marlink R., et al. New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). Science 1986, 232:238-243.
10. Hirsch V.M., Edmondson P., Murphey-Corb M., Arbeille B., Johnson P.R., Mullins J.I. SIV adaptation to human cells. Nature 1989, 341:573-574.
11. Huang M.L., Essex M., Lee T.H. Localization of immunogenic domains in the human immunodeficiency virus type 2 envelope. J Virol 1991, 65:5073-5079.
12. Sharp P.M., Hahn B.H. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011, 1:a006841.
13. Plantier J.C., Damond F., Souquieres S., Brun-Vezinet F., Simon F., Barin F. V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant. J Clin Microbiol 2001, 39:3803-3807.
14. Hu D.J., Dondero T.J., Rayfield M.A., George J.R., Schochetman G., Jaffe H.W., et al. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA 1996, 275:210-216.
15. Reeves J.D., Doms R.W. Human immunodeficiency virus type 2. J Gen Virol 2002, 83:1253-1265.
16. Peeters M., Toure-Kane C., Nkengasong J.N. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 2003, 17:2547-2560.
17. Rowland-Jones S.L., Whittle H.C. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1. Nat Immunol 2007, 8:329-331.
18. Marlink R., Kanki P., Thior I., Travers K., Eisen G., Siby T., et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994, 265:1587-1590.
19. Schim van der Loeff M.F., Larke N., Kaye S., Berry N., Ariyoshi K., Alabi A., et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010, 7:46.
20. Poulsen A.G., Aaby P., Larsen O., Jensen H., Naucler A., Lisse I.M., et al. 9-Year HIV-2-associated mortality in an urban community in Bissau, W. Africa. Lancet 1997, 349:911-914.
21. Darby S.C., Ewart D.W., Giangrande P.L., Dolin P.J., Spooner R.J., Rizza C.R. Mortality before and after HIV infection in the complete UK population of haemophiliacs. UK Haemophilia Centre Directors' Organisation. Nature 1995, 377:79-82.
22. Martinez-Steele E., Awasana A.A., Corrah T., Sabally S., van der Sande M., Jaye A., et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007, 21:317-324.
23. Hamel D.J., Sankale J.L., Eisen G., Meloni S.T., Mullins C., Gueye-Ndiaye A., et al. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses 2007, 23:1189-1196.
24. da Silva Z.J., Oliveira I., Andersen A., Dias F., Rodrigues A., Holmgren B., et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing. AIDS 2008, 22:1195-1202.
25. Sousa A.E., Carneiro J., Meier-Schellersheim M., Grossman Z., Victorino R.M.C.D4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002, 169:3400-3406.
26. Hegedus A., Nyamweya S., Zhang Y., Govind S., Aspinall R., Mashanova A., et al. Protection versus pathology in aviremic and high viral load HIV-2 infection - the pivotal role of immune activation and T-cell kinetics. J Infect Dis 2014, 210:752-761.
27. Leligdowicz A., Feldmann J., Jaye A., Cotten M., Dong T., McMichael A., et al. Direct relationship between virus load and systemic immune activation in HIV-2 infection. J Infect Dis 2010, 201:114-122.
28. Duvall M.G., Jaye A., Dong T., Brenchley J.M., Alabi A.S., Jeffries D.J., et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol 2006, 176:6973-6981.
29. Leligdowicz A., Yindom L.M., Onyango C., Sarge-Njie R., Alabi A., Cotten M., et al. Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest 2007, 117:3067-3074.
30. de Silva T.I., Peng Y., Leligdowicz A., Zaidi I., Li L., Griffin H., et al. Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection. Blood 2013, 121:4330-4339.
31. Duvall M.G., Lore K., Blaak H., Ambrozak D.A., Adams W.C., Santos K., et al. Dendritic cells are less susceptible to HIV-2 than HIV-1 infection. J Virol 2007, 81:13486-13498.
32. Marchant D., Neil S.J., McKnight A. Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J Gen Virol 2006, 87:411-418.
33. Rodriguez S.K., Sarr A.D., MacNeil A., Thakore-Meloni S., Gueye-Ndiaye A., Traore I., et al. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J Virol 2007, 81:5331-5338.
34. Minardi da Cruz J.C., Singh D.K., Lamara A., Chebloune Y. Small ruminant lentiviruses (SRLVs) break the species barrier to acquire new host range. Viruses 2013, 5:1867-1884.
35. Gao F., Bailes E., Robertson D.L., Chen Y., Rodenburg C.M., Michael S.F., et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999, 397:436-441.
36. Peeters M., Gueye A., Mboup S., Bibollet-Ruche F., Ekaza E., Mulanga C., et al. Geographical distribution of HIV-1 group O viruses in Africa. AIDS 1997, 11:493-498.
37. Vallari A., Holzmayer V., Harris B., Yamaguchi J., Ngansop C., Makamche F., et al. Confirmation of putative HIV-1 group P in Cameroon. J Virol 2011, 85:1403-1407.
38. Hirsch V.M., Olmsted R.A., Murphey-Corb M., Purcell R.H., Johnson P.R. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989, 339:389-392.
39. Silvestri G. Naturally SIV-infected sooty mangabeys: are we closer to understanding why they do not develop AIDS. J Med Primatol 2005, 34:243-252.
40. Apetrei C., Metzger M.J., Richardson D., Ling B., Telfer P.T., Reed P., et al. Detection and partial characterization of simian immunodeficiency virus SIVsm strains from bush meat samples from rural Sierra Leone. J Virol 2005, 79:2631-2636.
41. Damond F., Apetrei C., Robertson D.L., Souquiere S., Lepretre A., Matheron S., et al. Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in France. Virology 2001, 280:19-30.
42. Pieniazek D., Ellenberger D., Janini L.M., Ramos A.C., Nkengasong J., Sassan-Morokro M., et al. Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 1999, 15:603-608.
43. Bohl C., Bowder D., Thompson J., Abrahamyan L., Gonzalez-Ramirez S., Mao Y., et al. A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization. PLOS ONE 2013, 8:e69406.
44. Douagi I., Forsell M.N., Sundling C., O'Dell S., Feng Y., Dosenovic P., et al. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J Virol 2010, 84:1683-1695.
45. Moore J.P., Willey R.L., Lewis G.K., Robinson J., Sodroski J. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J Virol 1994, 68:6836-6847.
46. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393:705-711.
47. Barroso H., Borrego P., Bartolo I., Marcelino J.M., Familia C., Quintas A., et al. Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection. PLoS ONE 2011, 6:e14548.
48. Marcelino J.M., Borrego P., Rocha C., Barroso H., Quintas A., Novo C., et al. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. J Virol 2010, 84:12429-12436.
49. de Jong J.J., Goudsmit J., Keulen W., Klaver B., Krone W., Tersmette M., et al. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992, 66:757-765.
50. Hoffman N.G., Seillier-Moiseiwitsch F., Ahn J., Walker J.M., Swanstrom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002, 76:3852-3864.
51. Hwang S.S., Boyle T.J., Lyerly H.K., Cullen B.R. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991, 253:71-74.
52. Saunders C.J., McCaffrey R.A., Zharkikh I., Kraft Z., Malenbaum S.E., Burke B., et al. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol 2005, 79:9069-9080.
53. Gorny M.K., Pan R., Williams C., Wang X.H., Volsky B., O'Neal T., et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 2012, 427:198-207.
54. Ringe R., Phogat S., Bhattacharya J. Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies. Virology 2012, 426:34-41.
55. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
56. Skar H., Borrego P., Wallstrom T.C., Mild M., Marcelino J.M., Barroso H., et al. HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. J Virol 2010, 84:7412-7415.
57. de Silva T.I., Aasa-Chapman M., Cotten M., Hue S., Robinson J., Bibollet-Ruche F., et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol 2012, 86:930-946.
58. Marcelino J.M., Borrego P., Nilsson C., Familia C., Barroso H., Maltez F., et al. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. AIDS 2012, 26:2275-2284.
59. Doms R.W. Chemokine receptors and HIV entry. AIDS 2001, 15(Suppl. 1):S34-S35.
60. Lin G., Bertolotti-Ciarlet A., Haggarty B., Romano J., Nolan K.M., Leslie G.J., et al. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists. J Virol 2007, 81:9956-9966.
61. Azevedo-Pereira J.M., Lourenco M.H., Barin F., Cisterna R., Denis F., Moncharmont P., et al. Multicenter evaluation of a fully automated screening test, VIDAS HIV 1+2, for antibodies to human immunodeficiency virus types 1 and 2. J Clin Microbiol 1994, 32:2559-2563.
62. Marcelino J.M., Barroso H., Goncalves F., Silva S.M., Novo C., Gomes P., et al. Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. J Clin Microbiol 2006, 44:607-611.
63. Marcelino J.M., Nilsson C., Barroso H., Gomes P., Borrego P., Maltez F., et al. Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. AIDS 2008, 22:2257-2265.
64. Tendeiro R., Fernandes S., Foxall R.B., Marcelino J.M., Taveira N., Soares R.S., et al. Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia. AIDS 2012, 26:1607-1617.
65. Lugada E.S., Mermin J., Asjo B., Kaharuza F., Downing R., Langeland N., et al. Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway. Scand J Immunol 2004, 59:203-208.
66. Gordon S.N., Klatt N.R., Bosinger S.E., Brenchley J.M., Milush J.M., Engram J.C., et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 2007, 179:3026-3034.
67. Lizeng Q., Skott P., Sourial S., Nilsson C., Andersson S.S., Ehnlund M., et al. Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology 2003, 308:225-232.
68. Cavaleiro R., Brunn G.J., Albuquerque A.S., Victorino R.M., Platt J.L., Sousa A.E. Monocyte-mediated T cell suppression by HIV-2 envelope proteins. Eur J Immunol 2007, 37:3435-3444.
69. Trkola A., Kuster H., Leemann C., Oxenius A., Fagard C., Furrer H., et al. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 2004, 104:1784-1792.
70. Bjorling E., Chiodi F., Utter G., Norrby E. Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2. J Immunol 1994, 152:1952-1959.
71. van Gils M.J., Euler Z., Schweighardt B., Wrin T., Schuitemaker H. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 2009, 23:2405-2414.
72. Ozkaya Sahin G., Holmgren B., da Silva Z., Nielsen J., Nowroozalizadeh S., Esbjornsson J., et al. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol 2012, 86:961-971.
73. Kong R., Li H., Bibollet-Ruche F., Decker J.M., Zheng N.N., Gottlieb G.S., et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 2012, 86:947-960.
74. Bailey J.R., Lassen K.G., Yang H.C., Quinn T.C., Ray S.C., Blankson J.N., et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006, 80:4758-4770.
75. Schief W.R., Ban Y.E., Stamatatos L. Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 2009, 4:431-440.
76. Kong R., Li H., Georgiev I., Changela A., Bibollet-Ruche F., Decker J.M., et al. Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol 2012, 86:12115-12128.
77. Rusert P., Krarup A., Magnus C., Brandenberg O.F., Weber J., Ehlert A.K., et al. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med 2011, 208:1419-1433.
78. Chen L., Kwon Y.D., Zhou T., Wu X., O'Dell S., Cavacini L., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009, 326:1123-1127.
79. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
80. Shi Y., Brandin E., Vincic E., Jansson M., Blaxhult A., Gyllensten K., et al. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 2005, 86:3385-3396.
81. Ozkaya Sahin G., Holmgren B., Sheik-Khalil E., da Silva Z., Nielsen J., Nowroozalizadeh S., et al. Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent. J Virol 2013, 87:273-281.
82. Palmer E., Martin M.L., Goldsmith C., Switzer W. Ultrastructure of human immunodeficiency virus type 2. J Gen Virol 1988, 69(Pt 6):1425-1429.
83. Zhu P., Liu J., Bess J., Chertova E., Lifson J.D., Grise H., et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847-852.
84. Thomas E.R., Shotton C., Weiss R.A., Clapham P.R., McKnight A. CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS 2003, 17:291-300.
85. Borrego P., Marcelino J.M., Rocha C., Doroana M., Antunes F., Maltez F., et al. The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. Retrovirology 2008, 5:78.
86. Barroso H., Taveira N. Evidence for negative selective pressure in HIV-2 evolution in vivo. Infect Genet Evol 2005, 5:239-246.
87. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028.
88. Ren X., Sodroski J., Yang X. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. J Virol 2005, 79:5616-5624.
89. Rocha C., Calado R., Borrego P., Marcelino J.M., Bartolo I., Rosado L., et al. Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response. Retrovirology 2013, 10:110.